Gene therapy for neurological disorders: progress and prospects

被引：0
作者：
Benjamin E. Deverman
Bernard M. Ravina
Krystof S. Bankiewicz
Steven M. Paul
Dinah W. Y. Sah
机构：
[1] California Institute of Technology,Division of Biology and Biological Engineering
[2] Voyager Therapeutics,Department of Neurological Surgery
[3] University of California–San Francisco,undefined
[4] Present address: Stanley Center for Psychiatric Research at Broad Institute,undefined
[5] Cambridge,undefined
[6] MA,undefined
[7] USA.,undefined
来源：
Nature Reviews Drug Discovery | 2018年 / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The potential of adeno-associated viral (AAV)-mediated gene therapy for neurological disorders is rapidly emerging. Evidence of clinical efficacy and safety, as well as durable transgene expression, has now been reported in several central nervous system disorders. Here, Sah and colleagues discuss key considerations in the design and development of therapeutic AAV vectors, highlighting promising therapeutic targets and recent clinical trials.
引用
收藏
页码：641 / 659
页数：18
相关论文
共 407 条
[21]  
McCarty DM(2014)Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy Mol. Ther. Methods Clin. Dev. 1 14044-106
[22]  
Weismann CM(2016)An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models J. Neurosci. 36 12425-149
[23]  
Bailey RM(2017)Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice J. Exp. Med. 214 1227-3432
[24]  
Armao D(2015)AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy Nat. Biotechnol. 33 102-96
[25]  
Nagabhushan Kalburgi S(2016)In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 Nature 540 144-60
[26]  
Gray SJ(2000)In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration Proc. Natl Acad. Sci. USA 97 3428-1186
[27]  
Haurigot V(2008)Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system Mol. Ther. 16 89-317
[28]  
Garg SK(2012)AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method Gene Ther. 19 49-1342
[29]  
Gadalla KK(1998)Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector Hum. Gene Ther. 9 1181-859
[30]  
Gadalla KKE(2004)Selective and rapid uptake of adeno-associated virus type 2 in brain Mol. Ther. 10 302-1718
12345678910